SCHEMBL6380992

SCHEMBL6380992

O=C(/C=C/c1ccccc1)Nc1nncs1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.70
NPC1 O15118 5/20 0.70
KDM4E B2RXH2 5/20 0.70
SMN1; SMN2 Q16637 4/20 0.70
LMNA P02545 3/20 0.70
NFKB1 P19838 2/20 0.70
NFKB2 Q00653 2/20 0.70
RELA Q04206 2/20 0.70
KMT2A Q03164 2/20 0.62
TP53 P04637 1/20 0.62
ALDH1A1 P00352 3/20 0.60
MAPT P10636 2/20 0.60
PARP1 P09874 1/20 0.58
TAAR1 Q96RJ0 1/20 0.56
FSCN1 Q16658 1/20 0.56
MMP1 P03956 3/20 0.55
MMP2 P08253 3/20 0.55
MMP9 P14780 3/20 0.55
EGFR P00533 1/20 0.55
MAOA P21397 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6380999 1.00 RAB9A (0.70) RAB9ANPC1KDM4ESMN1; SMN2LMNA
SCHEMBL28645446 0.85 NPC1 (0.61) RAB9ANPC1KDM4ESMN1; SMN2LMNA
SCHEMBL31188414 0.85 NPC1 (0.61) RAB9ANPC1KDM4ESMN1; SMN2LMNA
SCHEMBL14757343 0.82 NPC1 (1.00) RAB9ANPC1KDM4ESMN1; SMN2LMNA
SCHEMBL13212221 0.81 AKT1 (0.64) KDM4ELMNAKMT2AALDH1A1MAPT
SCHEMBL19974323 0.80 NPC1 (0.58) RAB9ANPC1KDM4ESMN1; SMN2LMNA
SCHEMBL19974322 0.80 NPC1 (0.58) RAB9ANPC1KDM4ESMN1; SMN2LMNA
SCHEMBL18292499 0.73 LMNA (0.65) KDM4ELMNAKMT2AALDH1A1MAPT
SCHEMBL3379803 0.73 AQP4 (0.70) RAB9ANPC1KDM4ESMN1; SMN2LMNA
SCHEMBL28825761 0.73 LMNA (0.48) RAB9ANPC1KDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005072731-A1 3-PHENYL-N- ((1, 3, 4) THIADIAZOL-2-YL) -ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ESTROGEN-RELATED RECEPTORS FOR THE TREATMENT OF E.G. CANCER, RHEUMATOID ARTHRITIS OR NEUROLOGICAL DISORDERS X-CEPTOR THERAPEUTICS, INC. (US) 2005-08-11 WO disclosed